New Study Supports Use of Trimodal Therapy for MIBC
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
Bladder-sparing trimodal therapy with endoscopic resection, radiation therapy, and chemotherapy for muscle-invasive bladder cancer (MIBC) results in survival outcomes similar to those of selected matched patients undergoing radical cystecomy, researchers reported at the Canadian Urological Association 2016 annual meeting in Vancouver.
Girish S. Kulkarni, MD, and colleagues at Princess Margaret Cancer Centre in Toronto, compared 48 MIBC patients who underwent full bladder preservation with trimodal therapy (TMT) and a propensity score matched group of 48 MIBC patients who underwent RC, with no imbalances. After a median follow-up of 3.6 years, 19 patients in the RC group (39.6%) died (7 from bladder cancer) and 15 (31.3%) died in the TMT group (6 from bladder cancer). The 5-year disease-specific survival was 84.7% and 85.2% in the RC and TMT groups, respectively, a between-group difference that was not statistically significant.
See more coverage from the Canadian Urological Association meetings.